Skip to main content
SpringerLink
Log in

CNS Lymphoma

  • Chapter
  • First Online:
Rare Lymphomas

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1131 Accesses

Abstract

Central nervous system lymphoma (CNSL) may occur exclusively in the CNS (primary CNS lymphoma, PCNSL) or as a secondary involvement of a systemic lymphoma (secondary CNS lymphoma, SCNSL). The incidence of these lymphomas is still low, but an increasing incidence, particularly in older patients, has been reported in last decades. The pathophysiologic basis for development of lymphoma in the CNS, lacking a lymphatic system, is still a subject of debate. The course of CNSL is usually very aggressive and the prognosis worse compared to non-Hodgkin’s lymphoma involving other extranodal sites and organs. Therapeutic management has to account for the particular pharmacokinetics of the CNS. High-dose methotrexate (HDMTX) is the most active agent and should be considered backbone of therapy; however, the optimal management of CNSL has not been fully established. For long-term survivors, late neurotoxicity is an important issue, particularly when whole-brain radiotherapy (WBRT) was performed. Whenever possible, patients with CNS involvement of lymphoma should be included in clinical trials.

Pathology: German Ott and Eric D. Hsi

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859–863

    CAS  PubMed  Google Scholar 

  • Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144–3150

    CAS  PubMed  Google Scholar 

  • Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21(22):4151–4156

    Article  CAS  PubMed  Google Scholar 

  • Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F, International Primary CNS Lymphoma Collaborative Group (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034–5043. Epub 2005 Jun 13

    Article  PubMed  Google Scholar 

  • Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711–5715

    Article  PubMed  Google Scholar 

  • Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ (2000) High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6(3A):352–358

    Article  CAS  PubMed  Google Scholar 

  • Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R (2010) Cancer biomarkers in HIV patients. Curr Opin HIV AIDS 5:531–537

    Article  PubMed Central  PubMed  Google Scholar 

  • Angelov L, Doolittle ND, Kraemer DF et al (2009) Blood–brain barrier disruption and Intraarterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 27(21):3503–3509

    Article  CAS  PubMed  Google Scholar 

  • Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117(11):3140–3146

    Article  CAS  PubMed  Google Scholar 

  • Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21(6):1044–1049

    Article  CAS  PubMed  Google Scholar 

  • Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149–157. Epub 2006 Oct 3

    Article  CAS  PubMed  Google Scholar 

  • Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113(17):3896–3902

    Article  CAS  PubMed  Google Scholar 

  • Booman M, Douwes J, Glas AM et al (2006) Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphomas. Clin Cancer Res 12:2698–2705

    Article  CAS  PubMed  Google Scholar 

  • Borsi JD, Moe PJ (1987) A comparative study on the pharmacokinetics of methotrexate. In a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 60:5–13

    Article  CAS  PubMed  Google Scholar 

  • Braaten KM, Betensky RA, de Leval L et al (2003) BCL-6 expression predicts improved survival in patients with primary central nervous system lymphomas. Clin Cancer Res 9:1063–1069

    CAS  PubMed  Google Scholar 

  • Cady FM, O'Neill BP, Law ME et al (2008) Del(6)(q22) and BCL6 rearrangements in primary CNS lymphomas are indicators of an aggressive clinical course. J Clin Oncol 26:4814–4819

    Article  CAS  PubMed  Google Scholar 

  • Cavaliere R, Petroni G, Lopes MB, Schiff D (2010) Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphomas Collaborative Group Report. Cancer 116:863–870

    Article  PubMed  Google Scholar 

  • Chamberlain MC, Johnston SK (2010) High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol 12(7):736–744

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chan CC, Rubenstein JL, Coupland SE et al (2011) Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist 16(11):1589–1599

    Article  PubMed  Google Scholar 

  • Cinque P, Brytting M, Vago L et al (1993) Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphomas of the central nervous system. Lancet 342:398–401

    Article  CAS  PubMed  Google Scholar 

  • Collie A, Hsi ED (2013) Flow cytometric analysis of cerebrospinal fluid is low yield in samples without atypical morphology or prior history of hematologic malignancy. Am J Clin Pathol (in press)

    Google Scholar 

  • De Luca A, Antinori A, Cingolani A et al (1995) Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphomas. Br J Haematol 90: 844–849

    Article  PubMed  Google Scholar 

  • DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 20:4643–4648

    Article  PubMed  Google Scholar 

  • Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E (2008) Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 111(3):1085–1093

    Article  CAS  PubMed  Google Scholar 

  • Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel US, Rogowski S, Fu R, Dosa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA (2012) Long-term assessment and correlation of neuropsychological, neuroimaging and quality of life outcomes in primary CNS lymphoma survivor. American Society of Clinical Oncology annual meeting, Chicago, IL, 1–5 June 2012 (abstract 2040)

    Google Scholar 

  • Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5):901–903

    Article  CAS  PubMed  Google Scholar 

  • Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brander AA, Tosoni A et al (2006) MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 66:1435–1438

    Article  CAS  PubMed  Google Scholar 

  • Ferreri AJ, Reni M, Foppoli M, Pangalis GA, Frezzato M, Cabras MG et al (2009) High dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512–1520

    Article  CAS  PubMed  Google Scholar 

  • Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15(1):129–133

    Article  CAS  PubMed  Google Scholar 

  • Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P et al (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141–1145

    Article  CAS  PubMed  Google Scholar 

  • Fischer L, Korfel A, Pfeiffer S et al (2009a) CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 15:5968–5973

    Article  CAS  PubMed  Google Scholar 

  • Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E (2009b) CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 15(19):5968–5973

    Article  CAS  PubMed  Google Scholar 

  • Fischer L, Hummel M, Korfel A et al (2011a) Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 13: 1090–1098

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574

    Article  CAS  PubMed  Google Scholar 

  • Gerstner ER, Batchelor TT (2010) Primary central nervous system lymphomas. Arch Neurol 67:291–297

    Article  PubMed  Google Scholar 

  • Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphomas by immunohistochemistry using a tissue microarray. Blood 103:275–282

    Article  CAS  PubMed  Google Scholar 

  • Harder H, Holtel H, Bromberg JE et al (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544–547

    Article  CAS  PubMed  Google Scholar 

  • Hattab EM, Martin SE, Al-Khatib SM et al (2010) Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol 23:235–243

    Article  PubMed  Google Scholar 

  • Herrlinger U, Küker W, Uhl M, Blaicher HP, Karnath HO, Kranz L et al (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57:843–847

    Article  CAS  PubMed  Google Scholar 

  • Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F (2009) Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol 36(4 Suppl 2):S25–S34

    Article  CAS  PubMed  Google Scholar 

  • Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B, European Organization for Research and Treatment of Cancer Brain Tumor Group (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21(14): 2726–2731

    Article  CAS  PubMed  Google Scholar 

  • Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178–1182

    Article  PubMed  Google Scholar 

  • Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al (2006) High dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865–3870

    Article  CAS  PubMed  Google Scholar 

  • Jahnke K, Korfel A, O'Neill BP, Blay JY, Abrey LE, Martus P, Poortmans PM, Shenkier TN, Batchelor TT, Neuwelt EA, Raizer JJ, Schiff D, Pels H, Herrlinger U, Stein H, Thiel E (2006a) International study on low-grade primary central nervous system lymphoma. Ann Neurol 59(5):755–762

    Article  PubMed  Google Scholar 

  • Jahnke K, Hummel M, Korfel A et al (2006b) Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 24:4754–4757

    Article  CAS  PubMed  Google Scholar 

  • Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A (2006c) Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85(1):45–50

    Article  PubMed  Google Scholar 

  • Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U (2010) Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 67(2):182–189

    Article  CAS  PubMed  Google Scholar 

  • Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, Morrison C, Smith BD, Flinn IW (2005) High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 11(2):93–100

    Article  CAS  PubMed  Google Scholar 

  • Kelley TW, Prayson RA, Barnett GH et al (2005) Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue arising in the lateral ventricle. Leuk Lymphoma 46:1423–1427

    Article  CAS  PubMed  Google Scholar 

  • Knowles DM (2003) Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphomas. Hematol Oncol Clin North Am 17:785–820

    Article  PubMed  Google Scholar 

  • Korfel A (2011) Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol 23(5):436–440

    Article  PubMed  Google Scholar 

  • Korfel A, Weller M, Martus P, Roth P, Klasen HA, Roeth A, Rauch M, Hertenstein B, Fischer T, Hundsberger T, Leithäuser M, Birnbaum T, Kirchen H, Mergenthaler HG, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Fischer L (2012) Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Ann Oncol 23(9):2374–2380

    Article  CAS  PubMed  Google Scholar 

  • Korfel A, Etter T, Thiel E et al (2013) Phase II study of central nervous system (CSN) - directed chemotherapy including high - close chemotherapy with autologous stem cell transplantation for CNS relopse of aggressive lymphomas. Haematologine 98(3):364–70

    Article  CAS  Google Scholar 

  • Küker W, Nägele T, Thiel E, Weller M, Herrlinger U (2005) Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 65(7):1129–1131

    Article  PubMed  Google Scholar 

  • Laperriere HJ, Cerezo L, Milosevic MF, Wong CS, Patterson B, Panzarella T (1997) Primary lymphoma of brain: results of management of a modern cohort with radiation therapy. Radiother Oncol 43:247–252

    Article  CAS  PubMed  Google Scholar 

  • Levy O, Deangelis LM, Filippa DA et al (2008) Bcl-6 predicts improved prognosis in primary central nervous system lymphomas. Cancer 112:151–156

    Article  PubMed  Google Scholar 

  • Lin CH, Kuo KT, Chuang SS et al (2006) Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphomas of central nervous system origin and peripheral nodal origin. Clin Cancer Res 12:1152–1156

    Article  CAS  PubMed  Google Scholar 

  • Ly KI, Fintelmann F, Forghani R et al (2011) Novel diagnostic approaches in Bing-Neel syndrome. Clin Lymphomas Myeloma Leuk 11:180–183

    Article  Google Scholar 

  • Mazzucchelli L, Blaser A, Kappeler A et al (1999) BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest 104:R49–R54

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH (2009) Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood 113:4677–4680

    Article  CAS  PubMed  Google Scholar 

  • Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP et al (2000) A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89:1359–1370

    Article  CAS  PubMed  Google Scholar 

  • Momota H, Narita Y, Maeshima AM et al (2010) Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphomas. J Neurooncol 98:341–348

    Article  CAS  PubMed  Google Scholar 

  • Montesinos-Rongen M, Kuppers R, Schluter D et al (1999) Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 155:2077–2086

    Article  CAS  PubMed  Google Scholar 

  • Montesinos-Rongen M, Schmitz R, Brunn A et al (2010) Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphomas. Acta Neuropathol 120:529–535

    Article  CAS  PubMed  Google Scholar 

  • Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD et al (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9–17

    Article  CAS  PubMed  Google Scholar 

  • Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE (2010) Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 116(19):4605–4612

    Article  PubMed  Google Scholar 

  • Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg F, Batchelor TT, Loeffler JS (2003) Results of whole brain radiation as salvage of methotrexate failure for Immunocompetent patients with primary central nervous system lymphoma. J Clin Oncol 23:1507–1513

    Article  Google Scholar 

  • O’Brien PC, Roos DE, Pratt G, Liew KH, Barton MB, Poulson MG et al (2006) Combined modality therapy for primary central nervous system lymphoma: long-term data from a phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 64:408–413

    Article  PubMed  Google Scholar 

  • Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62(10): 1595–1600

    Article  PubMed  Google Scholar 

  • Patrij K, Reiser M, Watzel L, Pels H, Kowoll A, Herrlinger U et al (2011) Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci 9, ISSN 1612-3174

    Google Scholar 

  • Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V et al (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489–4495

    Article  CAS  PubMed  Google Scholar 

  • Pels H, Juergens A, Glasmacher A et al (2009) Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 91(3): 299–305

    Article  CAS  PubMed  Google Scholar 

  • Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10(17):5643–5646

    Article  CAS  PubMed  Google Scholar 

  • Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van’t Veer M, Hansen M, Soubeyran P et al (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21(24):4483–4488

    Article  CAS  PubMed  Google Scholar 

  • Preusser M, Woehrer A, Koperek O et al (2010) Primary central nervous system lymphomas: a clinicopathological study of 75 cases. Pathology 42:547–552

    Article  CAS  PubMed  Google Scholar 

  • Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M et al (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864–867

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Riemersma SA, Jordanova ES, Schop RF et al (2000) Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96:3569–3577

    CAS  PubMed  Google Scholar 

  • Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Röth A, Kaun S, Thiel E, Korfel A, Weller M (2012) Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 28:79(9)

    Google Scholar 

  • Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101(2):466–468

    Article  CAS  PubMed  Google Scholar 

  • Rubenstein JL, Fridlyand J, Shen A et al (2006) Gene expression and angiotropism in primary CNS lymphomas. Blood 107:3716–3723

    Article  CAS  PubMed  Google Scholar 

  • Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25(11):1350–1356

    Article  CAS  PubMed  Google Scholar 

  • Rubenstein JL, Hsi ED, Johnson JL et al (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31(25):3061–3068

    Article  CAS  PubMed  Google Scholar 

  • Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM, Spanish Group for the Study of CNS Disease in NHL (2010) Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol 85(4):321–328

    Article  CAS  PubMed  Google Scholar 

  • Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M et al (2012) CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 23(5): 1267–1273

    Article  CAS  PubMed  Google Scholar 

  • Schroers R, Baraniskin A, Heute C et al (2010a) Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 85:520–528

    Article  PubMed  Google Scholar 

  • Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, Schlegel U, Pels HJ (2010b) Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol 85(3):236–242. Epub 2010 May 26

    Article  CAS  PubMed  Google Scholar 

  • Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25(30):4730–4735. Erratum in: J Clin Oncol 26(2):340 (2008)

    Article  CAS  PubMed  Google Scholar 

  • Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal. Fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161–166

    Article  CAS  PubMed  Google Scholar 

  • Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, Braziel RM (2007) Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol 127:633–641

    Article  CAS  PubMed  Google Scholar 

  • Song MK, Chung JS, Joo YD et al (2011) Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphomas. J Neurooncol 104:825–831

    Article  CAS  PubMed  Google Scholar 

  • Soussain C, Hoang-Xuan K, Taillandier L et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26(15):2512–2518

    Article  PubMed  Google Scholar 

  • Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11(11):1036–1047

    Article  CAS  PubMed  Google Scholar 

  • Tu PH, Giannini C, Judkins AR et al (2005) Clinicopathologic and genetic profile of intracranial marginal zone lymphomas: a primary low-grade CNS lymphomas that mimics meningioma. J Clin Oncol 23:5718–5727

    Article  PubMed  Google Scholar 

  • Tun HW, Personett D, Baskerville KA et al (2008) Pathway analysis of primary central nervous system lymphoma. Blood 111:3200–3210

    Article  CAS  PubMed  Google Scholar 

  • Urrego PA, Smethurst M, Fowkes M et al (2011) Primary CNS plasmablastic lymphomas: report of a case with CSF cytology, flow cytometry, radiology, histological correlation, and review of the literature. Diagn Cytopathol 39:616–620

    Article  PubMed  Google Scholar 

  • Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21(5):1046–1052

    Article  CAS  PubMed  Google Scholar 

  • Weller M, Martus P, Roth P, Thiel E, Korfel A, German PCNSL Study Group (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14(12):1481–1484

    Article  PubMed Central  PubMed  Google Scholar 

  • Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL (2012) Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 18(4):1146–1155

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH (1994) Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome–a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 12(11):2415–2422

    CAS  PubMed  Google Scholar 

  • Yegappan S, Coupland R, Arber DA et al (2001) Angiotropic lymphomas: an immunophenotypically and clinically heterogeneous lymphomas. Mod Pathol 14:1147–1156

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany

    Agnieszka Korfel

  2. Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA

    James Rubenstein

  3. Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany

    German Ott MD

  4. Department of Clinical Pathology, Cleveland Clinic, L11, 9500 Euclid Ave, Cleveland, OH, 44195, USA

    Eric D. Hsi MD

Authors
  1. Agnieszka Korfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Rubenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. German Ott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric D. Hsi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agnieszka Korfel .

Editor information

Editors and Affiliations

  1. Medizinischen Klinik und Poliklinik III, Universität München Klinikum Großhadern, München, Germany

    Martin Dreyling

  2. Division of Hematology/Oncology and Cancer Center, University of Virginia Health System, Charlottesville, Virginia, USA

    Michael E. Williams

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Korfel, A., Rubenstein, J., Ott, G., Hsi, E.D. (2014). CNS Lymphoma. In: Dreyling, M., Williams, M. (eds) Rare Lymphomas. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39590-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39590-1_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39589-5

  • Online ISBN: 978-3-642-39590-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation